Dr. Khaleghi brings a wealth of experience in health technology and diagnostics to Molecular You

PORTLAND, Oregon, June 24, 2024 – Molecular You, a leading innovator in providing multi-biomarker testing and predictive health analytics, is pleased to announce the appointment of Dr. Murdoc Khaleghi as Chief Medical Officer (CMO).

Dr. Khaleghi brings a wealth of experience in health technology and diagnostics, having played instrumental roles in the launch and success of numerous companies in the field. Dr. Khaleghi holds degrees in medicine, bioengineering, computer science, and business, reflecting his multifaceted expertise and commitment to innovation in healthcare. Notably, he was a founding member of the Everlywell team and has held pivotal roles as Medical Director at prominent health tech startups including WellnessFX, Healium, NeuroTrack, and Me Biosciences.

“We are delighted to add Dr. Khaleghi to our world-class team at Molecular You,” said Jim Kean, CEO of Molecular You. “His track record of success in bridging the gaps between science, medicine, providers, and patients will be invaluable as we continue to expand our capabilities and bring transformative healthcare solutions to market.”

The company’s advanced molecular AI-powered blood analytics platform is driven by quantitative proteomics and metabolomics, accurately measuring over 250 blood biomarkers. The provider-facing platform, now overseen by Dr. Khaleghi, is available to clinics across the country, giving healthcare providers deeper insights into the health of their patients at the molecular level.

Commenting on his appointment, Dr. Murdoc Khaleghi said, “I am thrilled to join Molecular You at such a pivotal time in the company’s growth trajectory. Having witnessed the transformative data revealed by biomarker testing, Molecular You’s mission aligns perfectly with my passion for leveraging innovative solutions that improve both the provider and patient experience.”

Molecular You launched its platform in the Canadian market in 2022, and has been piloting with US-based clinics for the past year. The company is currently raising seed funding to further expand within the United States.